CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 63 enrolled
Drug / intervention
Ketorolac +1 moredrug
Likely dose
Ketorolac 0.5 mg/kg intravenouslyAI-extracted
Key inclusion· 3
  • Diagnosis of sleep disordered breathing or obstructive sleep apnea
  • Children undergoing elective tonsillectomy or adenotonsillectomy at Children's Healthcare of Atlanta Egleston location
  • Parent or legal guardian willing to participate and able to understand and sign informed consent
Key exclusion· 3
  • Known coagulation defect
  • Patients on longstanding NSAID therapy
  • Known renal impairment

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03467750
NCT03467750Phase 4Completed

Ketorolac as a Strategy for Reducing Post-operative Opioid Requirements in Children With Obstructive Sleep Apnea Undergoing Adenotonsillectomy: a Randomized Controlled Trial

Emory University·interventional·Posted Mar 16, 2018·Updated Sep 19, 2024

In Brief

A Phase 4 clinical trial evaluating Ketorolac and Standard of Care for Obstructive Sleep Apnea. Completed, enrolled 63 participants across 1 site.

Detailed Summary

This randomized prospective study aims to determine the effect of ketorolac on the total dose of morphine required to achieve postoperative analgesia in children with obstructive sleep apnea (OSA) undergoing adenotonsillectomy. Participants will be randomly assigned to a study group where they will receive ketorolac in addition to the standard of care treatment or will receive only the standard of care pain management. The researchers hypothesize that by administering ketorolac at the end of the procedure once hemostasis has been achieved, it will be possible to decrease the amount of morphine administered in the post-anesthesia care unit (PACU). This study aims to provide a more comprehensive understanding of the efficacy and safety of the current standard post-operative analgesic regimen employed at the study institution, in which opioid analgesia currently plays a prominent role.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedMar 16, 2018
Enrollment StartJul 19, 2018
Primary CompletionAug 22, 2023
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 8.3 years ago

Interventions

Ketorolacdrug

Patients in this group will receive 0.5mg/kg of ketorolac, administered intravenously.

Standard of Caredrug

All patients will undergo inhalational induction with nitrous oxide and sevoflurane. After intravenous (IV) placement, 1-3mg/kg of propofol and 1mcg/kg of fentanyl will be administered. After induction, 0.5mg/kg of dexamethasone and an IV infusion of 15mg/kg of acetaminophen will be administered. During surgery, 0.5mcg/kg of dexmedetomidine and 0.1mg/kg ondansetron will be given. A rescue dose of 0.5-1mcg/kg of IV Fentanyl will be available for use at the end of the procedure. The decision to administer will be left to the discretion of the attending anesthesiologist. The choice to give this will be made based on variables including patient's condition and a 20% increase in the heart rate and blood pressure. The PACU nurses, who will be blinded to ketorolac administration, will evaluate the patients using FLACC scores. For patients with a FLACC score of 6-10, morphine 0.05mg/kg will be administered. For patients with FLACC scores of 3-5, morphine 0.025mg/kg will be administered.